Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
BTIG analyst David Larsen reiterates Evolent Health (NYSE:EVH) with a Buy and maintains $20 price target.
Privia Health (PRVA) to acquire Evolent Health's (EVH) ACO business for $100M, expanding its value-based care footprint.
Stephens & Co. analyst Jeff Garro reiterates Evolent Health (NYSE:EVH) with a Equal-Weight and maintains $9 price target.
Evolent Health (NYSE:EVH) affirms Q3 sales outlook from $460.000 million-$480.000 million to $460.000 million-$480.000 million ...
Evolent Health (NYSE:EVH) affirms FY2025 sales outlook from $1.850 billion-$1.880 billion to $1.850 billion-$1.880 billion vs $...
BTIG analyst David Larsen reiterates Evolent Health (NYSE:EVH) with a Buy and maintains $20 price target.
